Phase I clinical trial of survivin‐derived peptide vaccine therapy for patients with advanced or rec...
Phase I clinical trial of survivin‐derived peptide vaccine therapy for patients with advanced or recurrent oral cancer
About this item
Full title
Author / Creator
Publisher
Oxford, UK: Blackwell Publishing Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Oxford, UK: Blackwell Publishing Ltd
Subjects
More information
Scope and Contents
Contents
Survivin, a member of the inhibitor of apoptosis protein (IAP) family, is abundantly expressed in most malignancies, but is hardly detectable in normal adult tissues. Previously we have identified a human leukocyte antigen (HLA)‐A24‐restricted antigenic peptide, survivin‐2B80‐88 (AYACNTSTL), recognized by CD8+ cytotoxic T lymphocytes (CTL). Survivi...
Alternative Titles
Full title
Phase I clinical trial of survivin‐derived peptide vaccine therapy for patients with advanced or recurrent oral cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_847594793
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_847594793
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/j.1349-7006.2010.01789.x
